Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of the allocation of stock-based compensation

The stock-based compensation expense attributable to option grants was allocated as follows:

	Three months ended March 31,
	2018			2017
Cost of product sales	$	50		$	—
Research and development cost		112			87
General and administrative expense		(18	)		74
Total	$	144		$	161

Schedule of assumptions used in the black-scholes-Merton option-pricing model

The following assumptions were used in the Black-Scholes-Merton pricing model to estimate the fair value of options granted during the periods presented.

	Three months ended March 31,
	2018	2017

Expected stock volatility	78.4%-79.9%	70.9%-72.2%
Risk free interest rate	2.06%-2.45%	1.53%-1.79%
Expected years until exercise	3.5	3.5
Dividend yield	0%	0%